- Home
- RVPH vs SGA Comparison
RVPH vs SGA Comparison
Compare RVPH & SGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- SGA
- Stock Information
- Founded
- RVPH 2006
- SGA 1986
- Country
- RVPH United States
- SGA United States
- Employees
- RVPH N/A
- SGA N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- SGA Broadcasting
- Sector
- RVPH Health Care
- SGA Consumer Discretionary
- Exchange
- RVPH Nasdaq
- SGA Nasdaq
- Market Cap
- RVPH 88.0M
- SGA 79.0M
- IPO Year
- RVPH N/A
- SGA 1992
- Fundamental
- Price
- RVPH $1.39
- SGA $11.67
- Analyst Decision
- RVPH Strong Buy
- SGA
- Analyst Count
- RVPH 5
- SGA 0
- Target Price
- RVPH $11.40
- SGA N/A
- AVG Volume (30 Days)
- RVPH 1.4M
- SGA 12.5K
- Earning Date
- RVPH 04-14-2025
- SGA 03-06-2025
- Dividend Yield
- RVPH N/A
- SGA 8.55%
- EPS Growth
- RVPH N/A
- SGA N/A
- EPS
- RVPH N/A
- SGA 0.75
- Revenue
- RVPH N/A
- SGA $110,669,000.00
- Revenue This Year
- RVPH N/A
- SGA N/A
- Revenue Next Year
- RVPH N/A
- SGA $2.64
- P/E Ratio
- RVPH N/A
- SGA $15.58
- Revenue Growth
- RVPH N/A
- SGA N/A
- 52 Week Low
- RVPH $0.60
- SGA $10.75
- 52 Week High
- RVPH $4.33
- SGA $24.67
- Technical
- Relative Strength Index (RSI)
- RVPH 31.30
- SGA 34.14
- Support Level
- RVPH $1.36
- SGA $11.44
- Resistance Level
- RVPH $1.88
- SGA $12.49
- Average True Range (ATR)
- RVPH 0.15
- SGA 0.33
- MACD
- RVPH -0.06
- SGA -0.13
- Stochastic Oscillator
- RVPH 7.59
- SGA 6.33
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets and It derives a majority of its revenue from the sale of advertising for broadcast on its stations.